Adaptive Biotechnologies raised its 2026 guidance as demand for its ClonoSeq minimal residual disease (MRD) assay continues to expand. Management forecasted 20%+ MRD revenue growth and said ClonoSeq test volume could rise roughly 30% year over year, citing increased adoption in community settings, EMR integrations and regulatory endorsement of MRD endpoints in trials. The company also signaled strengthening commercial fundamentals—higher average selling prices and broader clinical use—which could underpin MRD’s transition from niche research tool to scalable clinical diagnostic offering. Adaptive’s outlook will be watched as a bellwether for blood‑based diagnostics and the commercialization of MRD as a clinical decision point.